Multiple Sclerosis
First Patient Screened in Phase 2 Trial with RegeneRx's RGN-259 for Dry Eye Syndrome
Published in Medical Letter on the CDC and FDA, January 9th, 2011
2011 JAN 9 -- RegeneRx Biopharmaceuticals, Inc. (NYSE Amex: RGN) ("the Company" or "RegeneRx") announced that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tb4.
The clinical trial is being conducted under a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Public Health
New public health findings from Center for Disease Control described - Vaccines
NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus RSV Virus-like Particle VLP Vaccine Candidate - Plague Vaccines
Investigators at Trudeau Institute have published new data on plague vaccines - Clostridium Infections
Data from Stanford University provide new insights into clostridium infections - Genetics and Experimental Medicine
Scientists at National Center for Toxicological Research report research in genetics and experimental medicine - Antimicrobials
Researchers at University of Naples have published new data on antimicrobials - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
